|
1
|
Li D, Xie K, Wolff R and Abbruzzese JL:
Pancreatic cancer. Lancet. 363:1049–1057. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo X and Cui Z: Current diagnosis and
treatment of pancreatic cancer in China. Pancreas. 31:13–22. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hao J, Zhang S, Zhou Y, Hu X and Shao C:
MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in
pancreatic cancer. FEBS Lett. 585:207–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 66:7–30. 2017. View Article : Google Scholar
|
|
5
|
Fuchs CS, Colditz GA, Stampfer MJ,
Giovannucci EL, Hunter DJ, Rimm EB, Willett WC and Speizer FE: A
prospective study of cigarette smoking and the risk of pancreatic
cancer. Arch Intern Med. 156:2255–2260. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gapstur SM, Gann PH, Lowe W, Liu K,
Colangelo L and Dyer A: Abnormal glucose metabolism and pancreatic
cancer mortality. JAMA. 283:2552–2558. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Michaud DS, Giovannucci E, Willett WC,
Colditz GA, Stampfer MJ and Fuchs CS: Physical activity, obesity,
height, and the risk of pancreatic cancer. JAMA. 286:921–929. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dhayat SA, Abdeen B, Köhler G, Senninger
N, Haier J and Mardin WA: MicroRNA-100 and microRNA-21 as markers
of survival and chemotherapy response in pancreatic ductal
adenocarcinoma UICC stage II. Clin Epigenetics. 7:1322015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Couch FJ, Johnson MR, Rabe KG, Brune K, de
Andrade M, Goggins M, Rothenmund H, Gallinger S, Klein A, Petersen
GM and Hruban RH: The prevalence of BRCA2 mutations in familial
pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 16:342–346.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Abbruzzese JL: The challenge of pancreatic
cancer. Int J Gastrointest Cancer. 33:1–2. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hezel AF, Kimmelman AC, Stanger BZ,
Bardeesy N and Depinho RA: Genetics and biology of pancreatic
ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shi C, Daniels JA and Hruban RH: Molecular
characterization of pancreatic neoplasms. Adv Anat Pathol.
15:185–195. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhardwaj A, Singh S and Singh AP:
MicroRNA-based cancer therapeutics: Big hope from small RNAs. Mol
Cell Pharmacol. 2:213–219. 2010.PubMed/NCBI
|
|
14
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Boudreau RL, Jiang P, Gilmore BL, Spengler
RM, Tirabassi R, Nelson JA, Ross CA, Xing Y and Davidson BL:
Transcriptome-wide discovery of microRNA binding sites in human
brain. Neuron. 81:294–305. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gironella M, Seux M, Xie MJ, Cano C,
Tomasini R, Gommeaux J, Garcia S, Nowak J, Yeung ML, Jeang KT, et
al: Tumor protein 53-induced nuclear protein 1 expression is
repressed by miR-155 and its restoration inhibits pancreatic tumor
development. Proc Natl Acad Sci USA. 104:16170–16175. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iorio MV, Ferracin M, Liu CG, Veronese A,
Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M,
et al: MicroRNA gene expression deregulation in human breast
cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takamizawa J, Konishi H, Yanagisawa K,
Tomida S, Osada H, Endoh H, Harano T, Yatabe Y, Nagino M, Nimura Y,
et al: Reduced expression of the let-7 microRNAs in human lung
cancers in association with shortened postoperative survival.
Cancer Res. 64:3753–3756. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Naderi E, Mostafaei M, Pourshams A and
Mohamadkhani A: Network of microRNAs-mRNAs interactions in
pancreatic cancer. Biomed Res Int. 2014:5348212014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin S, Zhu Y, Ai F, Li Y, Bai B, Yao W and
Dong L: MicroRNA-191 correlates with poor prognosis of colorectal
carcinoma and plays multiple roles by targeting tissue inhibitor of
metalloprotease 3. Neoplasma. 61:27–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu H, Xu XF, Zhao Y, Tang MC, Zhou YQ, Lu
J and Gao FH: MicroRNA-191 promotes pancreatic cancer progression
by targeting USP10. Tumour Biol. 35:12157–12163. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He D, Miao H, Xu Y, Xiong L, Wang Y, Xiang
H, Zhang H and Zhang Z: MiR-371-5p facilitates pancreatic cancer
cell proliferation and decreases patient survival. PLoS One.
9:e1129302014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Feldmann G, Beaty R, Hruban RH and Maitra
A: Molecular genetics of pancreatic intraepithelial neoplasia. J
Hepatobiliary Pancreat Surg. 14:224–232. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bai Z, Sun J, Wang X, Wang H, Pei H and
Zhang Z: MicroRNA-153 is a prognostic marker and inhibits cell
migration and invasion by targeting SNAI1 in human pancreatic
ductal adenocarcinoma. Oncol Rep. 34:595–602. 2015.PubMed/NCBI
|
|
27
|
Subramani R, Gangwani L, Nandy SB,
Arumugam A, Chattopadhyay M and Lakshmanaswamy R: Emerging roles of
microRNAs in pancreatic cancer diagnosis, therapy and prognosis
(Review). Int J Oncol. 47:1203–1210. 2015.PubMed/NCBI
|
|
28
|
Xu C, Li S, Chen T, Hu H, Ding C, Xu Z,
Chen J, Liu Z, Lei Z, Zhang HT, et al: miR-296-5p suppresses cell
viability by directly targeting PLK1 in non-small cell lung cancer.
Oncol Rep. 35:497–503. 2016.PubMed/NCBI
|
|
29
|
Lee KH, Lin FC, Hsu TI, Lin JT, Guo JH,
Tsai CH, Lee YC, Lee YC, Chen CL, Hsiao M and Lu PJ:
MicroRNA-296-5p (miR-296-5p) functions as a tumor suppressor in
prostate cancer by directly targeting Pin1. Biochim Biophys Acta.
1843:2055–2066. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Savi F, Forno I, Faversani A, Luciani A,
Caldiera S, Gatti S, Foa P, Ricca D, Bulfamante G, Vaira V and
Bosari S: miR-296/Scribble axis is deregulated in human breast
cancer and miR-296 restoration reduces tumour growth in vivo. Clin
Sci (Lond). 127:233–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei JJ, Wu X, Peng Y, Shi G, Basturk O,
Yang X, Daniels G, Osman I, Ouyang J, Hernando E, et al: Regulation
of HMGA1 expression by microRNA-296 affects prostate cancer growth
and invasion. Clin Cancer Res. 17:1297–1305. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li T, Lu YY, Zhao XD, Guo HQ, Liu CH, Li
H, Zhou L, Han YN, Wu KC, Nie YZ, et al: MicroRNA-296-5p increases
proliferation in gastric cancer through repression of
Caudal-related homeobox 1. Oncogene. 33:783–793. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hong L, Han Y, Zhang H, Li M, Gong T, Sun
L, Wu K, Zhao Q and Fan D: The prognostic and chemotherapeutic
value of miR-296 in esophageal squamous cell carcinoma. Ann Surg.
251:1056–1063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Agarwal E, Brattain MG and Chowdhury S:
Cell survival and metastasis regulation by Akt signaling in
colorectal cancer. Cell Signal. 25:1711–1719. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kang B, Hao C, Wang H, Zhang J, Xing R,
Shao J, Li W, Xu N, Lu Y and Liu S: Evaluation of
hepatic-metastasis risk of colorectal cancer upon the protein
signature of PI3K/AKT pathway. J Proteome Res. 7:3507–3515. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Buontempo F, Ersahin T, Missiroli S,
Senturk S, Etro D, Ozturk M, Capitani S, Cetin-Atalay R and Neri
ML: Inhibition of Akt signaling in hepatoma cells induces apoptotic
cell death independent of Akt activation status. Invest New Drugs.
29:1303–1313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xu N, Lao Y, Zhang Y and Gillespie DA:
Akt: A double-edged sword in cell proliferation and genome
stability. J Oncol. 2012:9517242012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cheng JQ, Ruggeri B, Klein WM, Sonoda G,
Altomare DA, Watson DK and Testa JR: Amplification of AKT2 in human
pancreatic cells and inhibition of AKT2 expression and
tumorigenicity by antisense RNA. Proc Natl Acad Sci USA.
93:3636–3641. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Altomare DA, Tanno S, De Rienzo A,
Klein-Szanto AJ, Tanno S, Skele KL, Hoffman JP and Testa JR:
Frequent activation of AKT2 kinase in human pancreatic carcinomas.
J Cell Biochem. 87:470–476. 2002. View Article : Google Scholar : PubMed/NCBI
|
